| Author | Message | ||
     Speaker Yavvanam Kaatesina Bewarse Username: Speaker Post Number: 5982 Registered: 04-2017 Rating: N/A |
dorikesindi Annai...Mar 2nd is the day.. ee lopu full swing plus solid investment pettaaali deeenlo.. If KemPharm’s KP415 is approved by the FDA on March 2, it will mark the first major improvement since the launch of Vyvanse in 2007, according to Bill Mitton, an Iowa-based investor. In 2003 the ADHD market was $2.3 billion. That market in 2024 is estimated to be $24 billion, with a year over year increase. Vyvanse was discovered by Travis Mickle and a team of young scientists at a company called New River. It was an amphetamine-based stimulant with perceived lower abuse potential. Vyvanse was picked up by Shire for $2.6 billion. “Vyvnase has been a blockbuster for Shire and in fact, has been its top return-on-investment cash cow, since its inception,” Mitton said. However, fast forward to today. KemPharm, with the same Travis Mickle, now at the helm as CEO, along with the same team of scientists, anticipates that lightning will strike twice. The team has discovered a methylphenidate-based stimulant with properties that will propel it to be the category leader in a very short period of time, according to Mitton. “KemPharm believes it has developed a superior drug to the team’s original discovery of Vyvanse,” he said. The data for KP415 support the claim of a 30-minute onset of action, a smooth plasma profile and up to 13-hour duration. Anyone living in a household with a member or members afflicted with ADHD, knows how much of a vast improvement a 30-minute onset would be when compared to up to 90 minutes. That means the medication would be working by the time children are getting dressed and ready to go, instead of kicking in when they are dropped off at school. In addition, the 13-hour duration would be a lifesaver. It would allow the child to finish dinner and homework, without the need of having a booster medication later in the day. “Those attributes, along with less sleep disruption, a smooth efficacy curve and a HAP (Human Abuse Potential) comparable to a placebo, should make this a certain first-in-class drug.” Mitton explained. “Also, being a methylphenidate, which is preferred as a first choice in adolescents, is an asset.” He added, “We all know that having the product is key, but you also have to have a team that can effectively ramp up the distribution in order to be a blockbuster. More than a decade ago, Vyvanse was picked up by Shire. Shire had an ‘ace team,’ led by Perry Sternberg, that did a superb job in commercialization.” https://www.linkedin.com/pulse/kempharm-inc-kmph-builds-repurposing-molecules-da n-sfera/?trackingId=pSQNnszMRs2UGdnp5h8h1w%3D%3D Naa Maata, Nene Vinanu |